[Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs].
24 workers (10 involved in the preparation and 14 in administration) exposed to cyclophosphamide (CP) and ifosfamide (IF) in two Italian hospitals were monitored. The extent of exposure was assessed by the analysis of air samples, wipe samples, pads and gloves. Urinary excretion at the beginning and at the end of the work shift was also measured by liquid-liquid extraction and analysis by HPLC-MS/MS. 3 out of 24 air samples resulted to be positive for CP or IF. In wipe samples, CP concentrations ranging from < 0.001 to 82.4 micrograms/dm2 in Hospital A (32 samples) and from 0.2 to 383.3 micrograms/dm2 in Hospital B (17 samples), were found. IF concentrations varied from < 0.001 to 90.9 micrograms/dm2 in Hospital A and from 0.01 to 141.5 micrograms/dm2 in Hospital B. Pads (from 11 to 13 for each operator) were contaminated with CP and IF especially on arms, legs and chest. The use of a plastic-backed liner on the working tray in the laminar flow hoods was demonstrated to compromise the containment properties of the hood. Urine samples were positive for CP in 50% of the workers (range: 0.1-2.1 micrograms/L), whereas IF was detected in 2 subjects only (range: 0.1-0.8 microgram/L). The results from this investigation demonstrated that vertical laminar airflow hoods, when incorrectly used, might represent a source of contamination and that higher risk may depend on lack of educational programmes and observance of preventive guidelines.
Minoia
C
C
Laboratorio di Igiene Ambientale e Tossicologia Industriale, Fondazione S. Maugeri, Pavia.
Turci
R
R
Sottani
C
C
Schiavi
A
A
Perbellini
L
L
Angeleri
S
S
Frigerio
F
F
Draicchio
F
F
Apostoli
P
P
D000328:Adult; D000395:Air Pollutants, Occupational / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects* / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004339:Drug Compounding; D004784:Environmental Monitoring; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009784:Occupational Diseases / Q000139:chemically induced / Q000517:prevention & control*; D016273:Occupational Exposure / Q000517:prevention & control*; D010564:Personnel, Hospital; D018570:Risk Assessment; D011795:Surveys and Questionnaires
D000395:Air Pollutants, Occupational; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D007069:Ifosfamide